Date:2/5/2013

gative results from the Company’s clinical trials; the effects of government regulation on the Company’s business; risks associated with the Company’s ability to obtain and protect rights to its intellectual property; risks and uncertainties associated with the Company’s ability to raise additional capital; and other factors beyond the Company’s control. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward-looking statement speaks only as of the date on which such statement is made, and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2011 and other periodic reports filed from time-to-time with the Securities and Exchange Commission on Edgar at http://www.sec.gov and with the British Columbia Securities Commission on SEDAR at http://www.sedar.com.

Read the full story at http://www.prweb.com/releases/2013/2/prweb10390592.htm.

'/>"/>

Source: PRWeb Copyright©2012 Vocus, Inc. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Chandler Chicco Companies Acquires Haas & Health Partner Public Relations and SanCom Creative Communication Solutions, Creating Unrivalled Healthcare Communication Capability in Germany
2. EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics
3. Leading German Researcher Awarded Elseviers 2011 Tetrahedron Prize
4. World record: Scientists from northern Germany produce the lightest material in the world
5. Indian Pharma MNC Piramal Investing in German Molecular Imaging Technology
6. Marken Opens Two Pharmaceutical Depots In New York & Germany
7. Avery-Landsteiner Prize for Immunology Awarded to Alain Fischer of Paris, France, by German Society for Immunology
8. Germany Prioritizes Medical Biotechnology with New Initiatives
9. Northwest Biotherapeutics Appoints Pharma Industry Veteran As CEO Of German Subsidiary
10. France & Germany Blood Banking Market: Innovative Technologies and Emerging Business Opportunities in New Research Report at ReportsnReports.com
11. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors